A lack of understanding of terminology, health care system distrust, and a lack of prostate cancer knowledge are among the barriers to genomic testing for prostate cancer and prostate cancer research participation among black men.
Among cancer survivors, illness perception may affect patient health-related quality of life and mortality.
Odds of choosing screening up for men with family history, African descent, low socioeconomic status.
Findings for men with intermediate- and high-risk prostate cancer
The USPSTF has updated its 2012 recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer.
Prostate cancer was diagnosed more frequently in men who underwent single prostate-specific antigen screening than in those who did not, but mortality was unaffected.
For men with metastatic prostate cancer, aggressive therapy has no significant advantage over conservative androgen deprivation only treatments.
A positive correlation between increased BMI and risk of prostate cancer recurrence was observed in patients undergoing radical prostatectomy.
Polygenic hazard scores were developed to help predict the age of onset of prostate cancer.
A 20-year study found that patients with early-stage prostate cancer who have surgery to remove their tumor do not live longer than those who receive no treatment.
The USPSTF recommends that prostate cancer screenings should be an individual decision.
Antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival.
Cases of prostate biopsies resulting in the spread of cancerous cells are rare.
Vasectomy can continue to be a safe method of contraception in men.
A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were treated with ADT.
The analysis of diagnostic characteristics may predict the result of a confirmatory biopsy.
Patients treated with androgen deprivation therapy had a 1.88-times increased rate of developing Alzheimer's disease.
New research suggests that men with low-risk prostate cancer who undergo choose watchful waiting may not receive timely treatment when compared to those undergoing active treatment.
In the United States, the rate of prostate cancer screening is down, and the number of men diagnosed with the disease has also dropped.
Men should regularly be screened for prostate cancer, the leading cause of cancer death for men in the United States.
Higher doses of radiation does not increase survival rates in low-risk prostate cancer.
More targeted efforts needed for prostate-specific antigen screening.
Combination radiation and hormone therapy is more effective than hormone therapy alone for the treatment of prostate cancer.
PCPs should encourage physical activity, smoking cessation, and a healthy diet for PCa survivors.
Multiparametric magnetic resonance imaging reported high accuracy in diagnosing low-risk prostate cancers.
Low adherence rates for prostate cancer care may be target for future quality improvements.
Risk of long-term mortality is lower compared with watchful waiting.
Risk for advanced prostate cancer was 75% lower in men with high levels of 6-sulfatoxymelatonin -- a measure of melatonin breakdown in urine.
Even after adjustment, acute, chronic inflammation linked to lower PCa risk at two-year repeat biopsy.
Potential psychological harm associated with biopsy even in absence of cancer diagnosis